LABORATORIO REIG JOFRE stock analysis
LABORATORIO REIG JOFRE (0RB1) Share Price & Analysis
0RB1 Stock Chart & Stats
- Day’s Range
- EUR 2.60 - EUR 2.61
- 52-Week Range
- EUR 2.34 - EUR 2.82
- Previous Close
- EUR 2.63
- Volume
- N/A
- Average Volume (3M)
- 26
- Market Cap
- EUR 214.07M
- Enterprise Value
- EUR 329.17M
- Total Cash (Recent Filing)
- EUR 14.78M
- Total Debt (Recent Filing)
- EUR 119.58M
- Price to Earnings (P/E)
- 30.7
- Beta
- 0.24
- Next Earnings
- Feb 26, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.75%
Bulls Say, Bears Say
Bulls Say
Diversified Pharmaceutical Model
The combination of proprietary pharmaceutical products and CDMO services gives RJF more than one route to revenue. Its own portfolio can support product-led growth, while outsourced development and manufacturing use existing capabilities to broaden customer and market exposure.
Moderate Balance-sheet Leverage
Historically moderate leverage and gradual equity growth provide a degree of financial resilience for a pharmaceutical manufacturer. This balance-sheet foundation can support ongoing operations and selective investment, even though leverage increased in the latest year.
Prior Operating Track Record
The pre-2025 record shows that RJF had established revenue momentum and relatively consistent EBITDA margins over several years. That history indicates an operating platform capable of producing durable growth and profitability when conditions are supportive.
Bears Say
Sharp 2025 Revenue Contraction
The 2025 revenue decline represents a material interruption to RJF’s earlier growth trajectory. A contraction of this scale can reduce operating leverage, weaken absorption of fixed costs, and make recovery in earnings dependent on renewed demand or improved pricing.
Severe Cash-flow Deterioration
Negative free cash flow and sharply lower operating cash generation weaken RJF’s ability to fund investment and obligations internally. The volatility, including prior negative free cash flow in 2021, makes cash conversion less dependable over the medium term.
Profitability And Returns Weakened
The collapse in operating and net margins leaves limited earnings cushion if costs or commercial pressure persist. Lower ROE also indicates that the enlarged equity base is currently generating modest returns, reducing the company’s ability to compound shareholder value efficiently.
LABORATORIO REIG JOFRE News
0RB1 FAQ
What was LABORATORIO REIG JOFRE’s price range in the past 12 months?
What is LABORATORIO REIG JOFRE’s market cap?
When is LABORATORIO REIG JOFRE’s upcoming earnings report date?
How were LABORATORIO REIG JOFRE’s earnings last quarter?
Is LABORATORIO REIG JOFRE overvalued?
Does LABORATORIO REIG JOFRE pay dividends?
What is LABORATORIO REIG JOFRE’s EPS estimate?
How many shares outstanding does LABORATORIO REIG JOFRE have?
What happened to LABORATORIO REIG JOFRE’s price movement after its last earnings report?
Which hedge fund is a major shareholder of LABORATORIO REIG JOFRE?
What is the TipRanks Smart Score and how is it calculated?
Company Description
LABORATORIO REIG JOFRE
Laboratorio Reig Jofre, S.A. is a pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of a diverse range of medicines and nutritional supplements. Its extensive portfolio encompasses prescription drugs, over-the-counter (OTC) products, medical devices, and cosmetics. The company's offerings are categorized into several key areas: advanced pharmaceutical technologies, which include antibiotics and injectable formulations; specialized healthcare solutions targeting dermatological, musculoskeletal (joint health and pain), women's health, respiratory/ENT, and pediatric needs; and consumer health items marketed under its Forté Pharma brand. Furthermore, Laboratorio Reig Jofre provides contract development and manufacturing (CDMO) as well as contract manufacturing organization (CMO) services. Founded in 1929 and headquartered in Sant Joan Despí, Spain, the company sells its products directly in seven countries and collaborates with business partners to reach approximately 70 other nations. It operates as a subsidiary of Reig Jofre Investments SL.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Ignasi Biosca Reig
- Employees
- 1,400
- Website
- www.reigjofre.com
- Address
- Gran Capita, 10, Barcelona, CT, 08970, ES
LABORATORIO REIG JOFRE (0RB1) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 1 | 0 | 11 |








